Leerink Swann started coverage on shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report report published on Friday morning, MarketBeat.com reports. The brokerage issued a market perform rating and a $7.00 price objective on the biotechnology company’s stock.
Other research analysts have also issued reports about the stock. HC Wainwright reissued a buy rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. Zacks Investment Research lowered shares of Trillium Therapeutics from a buy rating to a hold rating and set a $8.75 target price on the stock. in a research note on Saturday, January 20th. Finally, ValuEngine lowered shares of Trillium Therapeutics from a hold rating to a sell rating in a research note on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $10.94.
TRIL opened at $7.05 on Friday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $13.30. The company has a market capitalization of $92.36, a price-to-earnings ratio of -1.99 and a beta of 1.83.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Artal Group S.A. acquired a new stake in shares of Trillium Therapeutics during the 4th quarter worth approximately $1,088,000. Citadel Advisors LLC acquired a new stake in shares of Trillium Therapeutics during the 4th quarter worth approximately $180,000. Victory Capital Management Inc. increased its holdings in shares of Trillium Therapeutics by 50.0% during the 4th quarter. Victory Capital Management Inc. now owns 218,971 shares of the biotechnology company’s stock worth $1,598,000 after buying an additional 72,950 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Trillium Therapeutics during the 4th quarter worth approximately $144,000. Finally, Deutsche Bank AG increased its holdings in shares of Trillium Therapeutics by 1,860.0% during the 4th quarter. Deutsche Bank AG now owns 115,288 shares of the biotechnology company’s stock worth $835,000 after buying an additional 109,406 shares during the last quarter. Institutional investors and hedge funds own 55.56% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/04/16/trillium-therapeutics-tril-receives-new-coverage-from-analysts-at-leerink-swann.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.